Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
RESEARCH TOOLSreports
Holding TSE:EPRX?
Track your performance easily
EPRX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$3.07 - C$7.64
Previous CloseC$5.03
Volume44.14K
Average Volume (3M)31.57K
Market Cap
C$166.45M
Enterprise ValueC$146.30M
Total Cash (Recent Filing)C$23.32M
Total Debt (Recent Filing)C$4.66M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Apr 01, 2025EPS Estimate
-C$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding35,622,553
10 Day Avg. Volume36,442
30 Day Avg. Volume31,571
Standard Deviation0.22
R-Squared0.04
Alpha0.00201
Financial Highlights & Ratios
Price to Book (P/B)11.98
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$12.58Price Target Upside165.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Eupraxia Pharmaceuticals News
PremiumCompany Announcements
Eupraxia Pharmaceuticals Unveils Promising Drug Delivery Data
PremiumCompany Announcements
Eupraxia Pharmaceuticals Showcases Innovation at ACR 2024
PremiumCompany Announcements
Eupraxia Pharmaceuticals Hosts Webinar on Digestive Disorders
PremiumCompany Announcements
Eupraxia Pharmaceuticals Reports Promising Trial ResultsOptions Prices
Currently, No data available
---
Ownership Overview
12.63% Insiders
3.96% Other Institutional Investors
83.41% Public Companies and
Individual Investors
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$3.07 and its highest was C$7.64 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Currently, no data Available
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 130 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -C$0.168 earnings per share for the quarter, beating the consensus estimate of -C$0.177 by C$0.009.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -C$0.2.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 35,622,555 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.168 in its last earnings report, beating expectations of -C$0.177. Following the earnings report the stock price went down -0.227%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
---
Eupraxia Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$12.58 (165.96% Upside)
C$12.58 (165.96% Upside)
Insider Transactions
Bought Shares
Worth C$7.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.24%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
---
EPRX Stock 12 Month Forecast
Average Price Target
C$12.58
▲(165.96% Upside)
Technical Analysis
Best Analysts Covering EPRX
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-27.60%
reiterated a buy rating 8 months ago
Copying Rahul Sarugaser's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -27.60% per trade.
---